
Stefan Schulz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5266436/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Regulation of <i>µ</i> -Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance. Pharmacological Reviews, 2013, 65, 223-254.	16.0	673
2	The Conserved Bardet-Biedl Syndrome Proteins Assemble a Coat that Traffics Membrane Proteins to Cilia. Cell, 2010, 141, 1208-1219.	28.9	542
3	CXCR4 Regulates Interneuron Migration in the Developing Neocortex. Journal of Neuroscience, 2003, 23, 5123-5130.	3.6	411
4	A Dual Role for the SDF-1/CXCR4 Chemokine Receptor System in Adult Brain: Isoform-Selective Regulation of SDF-1 Expression Modulates CXCR4-Dependent Neuronal Plasticity and Cerebral Leukocyte Recruitment after Focal Ischemia. Journal of Neuroscience, 2002, 22, 5865-5878.	3.6	366
5	Selective targeting of somatostatin receptor 3 to neuronal cilia. Neuroscience, 1999, 89, 909-926.	2.3	344
6	Homo- and Heterodimerization of Somatostatin Receptor Subtypes. Journal of Biological Chemistry, 2001, 276, 14027-14036.	3.4	274
7	Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. Journal of Neurochemistry, 2004, 89, 553-560.	3.9	263
8	Cxcr7 Controls Neuronal Migration by Regulating Chemokine Responsiveness. Neuron, 2011, 69, 77-90.	8.1	260
9	Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10444-10449.	7.1	235
10	Heterodimerization of Somatostatin and Opioid Receptors Cross-modulates Phosphorylation, Internalization, and Desensitization. Journal of Biological Chemistry, 2002, 277, 19762-19772.	3.4	227
11	Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nature Communications, 2019, 10, 367.	12.8	226
12	Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling, 2020, 13, .	3.6	219
13	Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut, 2002, 50, 52-60.	12.1	186
14	PET of CXCR4 Expression by a ⁶⁸ Ga-Labeled Highly Specific Targeted Contrast Agent. Journal of Nuclear Medicine, 2011, 52, 1803-1810.	5.0	182
15	Morphineâ€induced respiratory depression is independent of βâ€arrestin2 signalling. British Journal of Pharmacology, 2020, 177, 2923-2931.	5.4	182
16	Carboxyl-terminal Splicing of the Rat μ Opioid Receptor Modulates Agonist-mediated Internalization and Receptor Resensitization. Journal of Biological Chemistry, 1998, 273, 13652-13657.	3.4	172
17	Morphine induces terminal μ-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO Journal, 2004, 23, 3282-3289.	7.8	165
18	CXCR4 and Gab1 cooperate to control the development of migrating muscle progenitor cells. Genes and Development, 2005, 19, 2187-2198.	5.9	164

#	Article	IF	CITATIONS
19	International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacological Reviews, 2018, 70, 763-835.	16.0	163
20	Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 654-661.	3.6	156
21	Receptor Endocytosis Counteracts the Development of Opioid Tolerance. Molecular Pharmacology, 2005, 67, 280-287.	2.3	153
22	The Concise Guide to PHARMACOLOGY 2013/14: Overview. British Journal of Pharmacology, 2013, 170, 1449-1458.	5.4	153
23	C-terminal Splice Variants of the Mouse µ-Opioid Receptor Differ in Morphine-induced Internalization and Receptor Resensitization. Journal of Biological Chemistry, 2001, 276, 31408-31414.	3.4	150
24	Differential β-Arrestin Trafficking and Endosomal Sorting of Somatostatin Receptor Subtypes. Journal of Biological Chemistry, 2004, 279, 21374-21382.	3.4	150
25	Direct Evidence for Biphasic cAMP Responsive Element-Binding Protein Phosphorylation during Long-Term Potentiation in the Rat Dentate GyrusIn Vivo. Journal of Neuroscience, 1999, 19, 5683-5692.	3.6	142
26	Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies. Journal of Physiology (Paris), 2000, 94, 259-264.	2.1	137
27	Somatostatin Receptor Subtypes in Human Pheochromocytoma: Subcellular Expression Pattern and Functional Relevance for Octreotide Scintigraphy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5150-5157.	3.6	137
28	Heterodimerization of Substance P and μ-Opioid Receptors Regulates Receptor Trafficking and Resensitization. Journal of Biological Chemistry, 2003, 278, 51630-51637.	3.4	132
29	Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. Journal of Nuclear Medicine, 2006, 47, 502-11.	5.0	132
30	Targeting multiple opioid receptors – improved analgesics with reduced side effects?. British Journal of Pharmacology, 2018, 175, 2857-2868.	5.4	131
31	Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1659-1668.	6.4	130
32	Nociceptin/orphanin FQ and opioid peptides show overlapping distribution but not co-localization in pain-modulatory brain regions. NeuroReport, 1996, 7, 3021-3026.	1.2	129
33	Identification and Characterization of Two Novel Truncated but Functional Isoforms of the Somatostatin Receptor Subtype 5 Differentially Present in Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2634-2643.	3.6	125
34	Comparison of immunoreactive score, HER2/ <i>neu</i> score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms. Histopathology, 2015, 67, 368-377.	2.9	123
35	Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1411-E1420.	3.6	122
36	Regional and cellular localization of the CXCl12/SDFâ€1 chemokine receptor CXCR7 in the developing and adult rat brain. Journal of Comparative Neurology, 2008, 510, 207-220.	1.6	118

#	Article	IF	CITATIONS
37	Agonist-selective patterns of µ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. British Journal of Pharmacology, 2011, 164, 298-307.	5.4	118
38	Somatostatin Signaling in Neuronal Cilia Is Criticalfor Object Recognition Memory. Journal of Neuroscience, 2010, 30, 4306-4314.	3.6	115
39	Reassessment of sst ₂ Somatostatin Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-1. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4519-4524.	3.6	114
40	Differentiation of Opioid Drug Effects by Hierarchical Multi-Site Phosphorylation. Molecular Pharmacology, 2013, 83, 633-639.	2.3	113
41	Anatomical characterization of the neuropeptide S system in the mouse brain by in situ hybridization and immunohistochemistry. Journal of Comparative Neurology, 2011, 519, 1867-1893.	1.6	112
42	Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1730-E1739.	3.6	112
43	Pain control by CXCR2 ligands through Ca 2+ â€regulated release of opioid peptides from polymorphonuclear cells. FASEB Journal, 2006, 20, 2627-2629.	0.5	110
44	Immunocytochemical localization of somatostatin receptor sst2Ain the rat spinal cord and dorsal root ganglia. European Journal of Neuroscience, 1998, 10, 3700-3708.	2.6	104
45	Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors. Journal of Clinical Oncology, 2008, 26, 963-970.	1.6	99
46	Distribution, Targeting, and Internalization of the sst ₄ Somatostatin Receptor in Rat Brain. Journal of Neuroscience, 2000, 20, 3785-3797.	3.6	98
47	Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone-Secreting Adenomas. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1203-1210.	3.6	98
48	Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid \hat{l}_{4} -opioid receptor desensitization. Science Signaling, 2018, 11, .	3.6	97
49	Enhanced expression of the CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat brain. Journal of Neuroimmunology, 2008, 198, 39-45.	2.3	94
50	ADP-ribosylation Factor-dependent Phospholipase D2 Activation Is Required for Agonist-induced μ-Opioid Receptor Endocytosis. Journal of Biological Chemistry, 2003, 278, 9979-9985.	3.4	91
51	Neuronal types expressing μ- and δ-opioid receptor mRNA in the rat hippocampal formation. Journal of Comparative Neurology, 2004, 469, 107-118.	1.6	91
52	Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor. Trends in Pharmacological Sciences, 2020, 41, 947-959.	8.7	91
53	Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 2960-2964.	7.1	90
54	Immunocytochemical Identification of VPAC1, VPAC2, and PAC1 Receptors in Normal and Neoplastic Human Tissues with Subtype-Specific Antibodies. Clinical Cancer Research, 2004, 10, 8235-8242.	7.0	90

#	Article	IF	CITATIONS
55	Involvement of Mitogen-Activated Protein Kinase in Agonist-Induced Phosphorylation of the μ-Opioid Receptor in HEK 293 Cells. Journal of Neurochemistry, 2001, 74, 414-422.	3.9	87
56	Patterns of SDF-1α and SDF-1Î ³ mRNAs, migration pathways, and phenotypes of CXCR4-expressing neurons in the developing rat telencephalon. Journal of Comparative Neurology, 2007, 502, 382-399.	1.6	86
57	Deciphering µâ€opioid receptor phosphorylation and dephosphorylation in HEK293 cells. British Journal of Pharmacology, 2012, 167, 1259-1270.	5.4	85
58	Pasireotide and Octreotide Stimulate Distinct Patterns of sst2A Somatostatin Receptor Phosphorylation. Molecular Endocrinology, 2010, 24, 436-446.	3.7	83
59	Colocalization of the μ-opioid receptor and calcium/calmodulin-dependent kinase II in distinct pain-processing brain regions. Molecular Brain Research, 2000, 85, 239-250.	2.3	81
60	Immunofluorescent identification of endomorphin-2-containing nerve fibers and terminals in the rat brain and spinal cord. NeuroReport, 1998, 9, 1031-1034.	1.2	80
61	Rapid Uptake and Degradation of CXCL12 Depend on CXCR7 Carboxyl-terminal Serine/Threonine Residues. Journal of Biological Chemistry, 2012, 287, 28362-28377.	3.4	79
62	Opioid withdrawal activates MAP kinase in locus coeruleus neurons in morphine-dependent ratsin vivo. European Journal of Neuroscience, 1998, 10, 1196-1201.	2.6	78
63	Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget, 2015, 6, 27566-27579.	1.8	77
64	Immunocytochemistry of endothelial nitric oxide synthase in the rat brain: a light and electron microscopical study using the tyramide signal amplification technique. Acta Histochemica, 1997, 99, 411-429.	1.8	76
65	Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. International Journal of Clinical and Experimental Pathology, 2012, 5, 187-94.	0.5	73
66	Immunolocalization of two mu-opioid receptor isoforms (MOR1 and MOR1B) in the rat central nervous system. Neuroscience, 1997, 82, 613-622.	2.3	71
67	Tonic Activation of CXC Chemokine Receptor 4 in Immature Granule Cells Supports Neurogenesis in the Adult Dentate Gyrus. Journal of Neuroscience, 2008, 28, 4488-4500.	3.6	71
68	New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting. Clinical Cancer Research, 2008, 14, 2019-2027.	7.0	68
69	Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. European Journal of Endocrinology, 2010, 162, 979-986.	3.7	65
70	Reassessment of sst ₅ Somatostatin Receptor Expression in Normal and Neoplastic Human Tissues Using the Novel Rabbit Monoclonal Antibody UMB-4. Neuroendocrinology, 2011, 94, 255-264.	2.5	65
71	Phospholipase D2 modulates agonist-induced µ-opioid receptor desensitization and resensitization. Journal of Neurochemistry, 2003, 88, 680-688.	3.9	64
72	Novel insights in somatostatin receptor physiology. European Journal of Endocrinology, 2007, 156, S3-S11.	3.7	64

#	Article	IF	CITATIONS
73	Identification of cells expressing somatostatin receptor 2 in the gastrointestinal tract ofSstr2 knockout/lacZ knockin mice. Journal of Comparative Neurology, 2002, 454, 329-340.	1.6	60
74	SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocrine-Related Cancer, 2015, 22, 111-119.	3.1	60
75	ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin. Cell Reports, 2019, 26, 1473-1488.e9.	6.4	60
76	Reassessment of CXCR4 Chemokine Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-2. PLoS ONE, 2008, 3, e4069.	2.5	59
77	Replacement of Threonine 394 by Alanine Facilitates Internalization and Resensitization of the Rat μ Opioid Receptor. Molecular Pharmacology, 1999, 55, 263-268.	2.3	58
78	Analgesic Tolerance to High-Efficacy Agonists But Not to Morphine Is Diminished in Phosphorylation-Deficient S375A μ-Opioid Receptor Knock-In Mice. Journal of Neuroscience, 2011, 31, 13890-13896.	3.6	55
79	DC3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. European Journal of Endocrinology, 2012, 166, 223-234.	3.7	55
80	GPCR kinase knockout cells reveal the impact of individual GRKs on arrestin binding and GPCR regulation. Nature Communications, 2022, 13, 540.	12.8	54
81	Allosteric modulation of metabotropic glutamate receptor 5 affects phosphorylation, internalization, and desensitization of the μ-opioid receptor. Neuropharmacology, 2009, 56, 768-778.	4.1	53
82	Membrane Glycoprotein M6a Interacts with the μ-Opioid Receptor and Facilitates Receptor Endocytosis and Recycling. Journal of Biological Chemistry, 2007, 282, 22239-22247.	3.4	52
83	Hierarchical Organization of Multi-Site Phosphorylation at the CXCR4 C Terminus. PLoS ONE, 2013, 8, e64975.	2.5	52
84	Somatostatin Receptor 2 Is Activated in Cortical Neurons and Contributes to Neurodegeneration after Focal Ischemia. Journal of Neuroscience, 2004, 24, 11404-11415.	3.6	51
85	Prenylated proteins and lymphocyte proliferation: Inhibition byd-limonene and related monoterpenes. European Journal of Immunology, 1994, 24, 301-307.	2.9	49
86	Balance between somatostatin and D2 receptor expression drives TSHâ€secreting adenoma response to somatostatin analogues and dopastatins. Clinical Endocrinology, 2012, 76, 407-414.	2.4	47
87	Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clinical Endocrinology, 2008, 68, 850-857.	2.4	46
88	Intracellular trafficking of somatostatin receptors. Molecular and Cellular Endocrinology, 2008, 286, 58-62.	3.2	46
89	Somatostatin Receptors in Bronchopulmonary Neuroendocrine Neoplasms: New Diagnostic, Prognostic, and Therapeutic Markers. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 831-840.	3.6	46
90	Heterologous regulation of agonistâ€independent μâ€opioid receptor phosphorylation by protein kinase <scp>C</scp> . British Journal of Pharmacology, 2014, 171, 1330-1340.	5.4	45

#	Article	IF	CITATIONS
91	Loss of Morphine Reward and Dependence in Mice Lacking G Protein–Coupled Receptor Kinase 5. Biological Psychiatry, 2014, 76, 767-774.	1.3	45
92	Phenotypic and Genotypic Characterization of Carcinomas of the Papilla of Vater Has Prognostic and Putative Therapeutic Implications. American Journal of Clinical Pathology, 2011, 135, 202-211.	0.7	44
93	Reassessment of sst ₃ Somatostatin Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-5. Neuroendocrinology, 2012, 96, 301-310.	2.5	44
94	Preoperative Normalization of Cortisol Levels in Cushing's Disease After Medical Treatment: Consequences for Somatostatin and Dopamine Receptor Subtype Expression and In Vitro Response to Somatostatin Analogs and Dopamine Agonists. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1880-E1890.	3.6	44
95	Alterations of Phospholamban Function Can Exhibit Cardiotoxic Effects Independent of Excessive Sarcoplasmic Reticulum Ca ²⁺ -ATPase Inhibition. Circulation, 2009, 119, 436-444.	1.6	43
96	Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immuneâ€mediated arthritis. Arthritis and Rheumatism, 2011, 63, 2352-2362.	6.7	43
97	Differential Expression of Somatostatin Receptor Subtype 1–5 Proteins in Numerous Human Normal Tissues. Experimental and Clinical Endocrinology and Diabetes, 2012, 120, 482-489.	1.2	43
98	Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1876-1885.	6.4	43
99	Inhibition of protein isoprenylation and p21ras membrane association by dehydroepiandrosterone in human colonic adenocarcinoma cells in vitro. Cancer Research, 1991, 51, 6563-7.	0.9	43
100	Mechanisms of cell growth inhibition and cell cycle arrest in human colonic adenocarcinoma cells by dehydroepiandrosterone: role of isoprenoid biosynthesis. Cancer Research, 1992, 52, 1372-6.	0.9	42
101	Differential distribution of alternatively spliced somatostatin receptor 2 isoforms (sst2A and sst2B) in rat spinal cord. Neuroscience Letters, 1998, 257, 37-40.	2.1	41
102	Somatostatin mediates nitric oxide production by activating sst2 receptors in the rat retina. Neuropharmacology, 2002, 43, 899-909.	4.1	41
103	Biomedical ontologies: What part-of is and isn't. Journal of Biomedical Informatics, 2006, 39, 350-361.	4.3	41
104	Different mechanisms of homologous and heterologous μâ€opioid receptor phosphorylation. British Journal of Pharmacology, 2015, 172, 311-316.	5.4	41
105	CXC Chemokine Receptor 7 (CXCR7) Regulates CXCR4 Protein Expression and Capillary Tuft Development in Mouse Kidney. PLoS ONE, 2012, 7, e42814.	2.5	40
106	Role of Phosphorylation Sites in Desensitization of <i>µ</i> -Opioid Receptor. Molecular Pharmacology, 2015, 88, 825-835.	2.3	40
107	Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. Journal of Nuclear Medicine, 2005, 46, 2097-103.	5.0	40
108	Somatostatin and its 2A Receptor in Dorsal Root Ganglia and Dorsal Horn of Mouse and Human: Expression, Trafficking and Possible Role in Pain. Molecular Pain, 2014, 10, 1744-8069-10-12.	2.1	39

#	Article	IF	CITATIONS
109	Design, Synthesis, and Biological Evaluation of Somatostatin-Based Radiopeptides. Chemistry and Biology, 2006, 13, 1081-1090.	6.0	38
110	Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: new aspects on Alzheimer's disease. Acta Neuropathologica, 2015, 129, 541-563.	7.7	36
111	Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists. Science Signaling, 2019, 12, .	3.6	36
112	Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms. Oncotarget, 2015, 6, 3346-3358.	1.8	36
113	Protective effects of cortistatin (CST-14) against kainate-induced neurotoxicity in rat brain. Brain Research, 1998, 803, 54-60.	2.2	35
114	Loss of locomotor sensitisation in response to morphine in D1 receptor deficient mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 562-568.	3.0	35
115	Rapid Dephosphorylation of G Protein-coupled Receptors by Protein Phosphatase 1β Is Required for Termination of β-Arrestin-dependent Signaling. Journal of Biological Chemistry, 2011, 286, 32931-32936.	3.4	34
116	Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2239-2247.	2.5	33
117	A Switch of G Protein-Coupled Receptor Binding Preference from Phosphoinositide 3-Kinase (PI3K)–p85 to Filamin A Negatively Controls the PI3K Pathway. Molecular and Cellular Biology, 2012, 32, 1004-1016.	2.3	32
118	The COMMD3/8 complex determines GRK6 specificity for chemoattractant receptors. Journal of Experimental Medicine, 2019, 216, 1630-1647.	8.5	32
119	Design of a multiple slice interface chamber and application for resolving the temporal pattern of CREB phosphorylation in hippocampal long-term potentiation. Journal of Neuroscience Methods, 1997, 78, 173-179.	2.5	31
120	Interaction of the human somatostatin receptor 3 with the multiple PDZ domain protein MUPP1 enables somatostatin to control permeability of epithelial tight junctions. FEBS Letters, 2009, 583, 49-54.	2.8	31
121	Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice. Arthritis Research and Therapy, 2011, 13, R97.	3.5	31
122	Inhibition by compactin demonstrates a requirement of isoprenoid metabolism for long-term potentiation in rat hippocampal slices. Neuroscience, 1997, 79, 341-346.	2.3	30
123	Leptin-Target Neurones of the Rat Hypothalamus Express Somatostatin Receptors. Journal of Neuroendocrinology, 2003, 15, 822-830.	2.6	30
124	Differential Expression of sst ₁ , sst _{2A} , and sst ₃ Somatostatin Receptor Proteins in Low-Grade and High-Grade Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2004, 63, 13-19.	1.7	30
125	Phosphorylation of Threonine 333 Regulates Trafficking of the Human sst5 Somatostatin Receptor. Molecular Endocrinology, 2013, 27, 671-682.	3.7	30
126	Cell-Autonomous Regulation of Mu-Opioid Receptor Recycling by Substance P. Cell Reports, 2015, 10, 1925-1936.	6.4	30

#	Article	IF	CITATIONS
127	Mechanisms of somatostatin-evoked responses in neurons of the rat lateral amygdala. European Journal of Neuroscience, 2005, 21, 755-762.	2.6	29
128	CXCL14 is no direct modulator of CXCR4. FEBS Letters, 2014, 588, 4769-4775.	2.8	29
129	Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies. Scientific Reports, 2020, 10, 8585.	3.3	29
130	Immunohistochemical Detection of Somatostatin Receptors in Human Ovarian Tumors. Gynecologic Oncology, 2002, 84, 235-240.	1.4	28
131	Modulation of μ-opioid receptor desensitization in peripheral sensory neurons by phosphoinositide 3-kinase γ. Neuroscience, 2010, 169, 449-454.	2.3	28
132	UMB-3, a novel rabbit monoclonal antibody, for assessing μ-opioid receptor expression in mouse, rat and human formalin-fixed and paraffin-embedded tissues. Regulatory Peptides, 2011, 167, 9-13.	1.9	28
133	Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay. Molecular Endocrinology, 2016, 30, 479-490.	3.7	28
134	Vascular CXCR4 Expression – a Novel Antiangiogenic Target in Gastric Cancer?. PLoS ONE, 2010, 5, e10087.	2.5	28
135	Inhibitory Role of the Somatostatin Receptor SST2 on the Intracrine-regulated Cell Proliferation Induced by the 210-Amino Acid Fibroblast Growth Factor-2 Isoform. Journal of Biological Chemistry, 2003, 278, 20574-20581.	3.4	27
136	Structural Determinants of Agonist-Selective Signaling at the sst2A Somatostatin Receptor. Molecular Endocrinology, 2011, 25, 859-866.	3.7	27
137	Emerging Paradigms of G Protein-Coupled Receptor Dephosphorylation. Trends in Pharmacological Sciences, 2017, 38, 621-636.	8.7	27
138	Perillic Acid Inhibits Ras/MAPkinase-Driven IL-2 Production in Human T Lymphocytes. Biochemical and Biophysical Research Communications, 1997, 241, 720-725.	2.1	26
139	Hormonal regulation of neonatal weight: placental leptin and leptin receptors. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1486-1491.	2.3	26
140	Immunohistochemical Determination of Somatostatin Receptor Subtypes 1, 2A, 3, 4, and 5 in Various Adrenal Tumors. Endocrine Research, 2004, 30, 931-934.	1.2	26
141	Immunolocalization of Full-length NK1 Tachykinin Receptors in Human Tumors. Journal of Histochemistry and Cytochemistry, 2006, 54, 1015-1020.	2.5	26
142	Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer, 2017, 17, 896.	2.6	26
143	Immunohistochemical detection of bombesin receptor subtypes GRP-R and BRS-3 in human tumors using novel antipeptide antibodies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 421-427.	2.8	25
144	Association of Somatostatin Receptor 2 Immunohistochemical Expression with [¹¹¹ In]-DTPA Octreotide Scintigraphy and [⁶⁸ Ga]-DOTATOC PET/CT in Neuroendocrine Tumors. Hormone and Metabolic Research, 2010, 42, 599-606.	1.5	25

#	Article	IF	CITATIONS
145	Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas. Oncotarget, 2017, 8, 89958-89969.	1.8	25
146	Reevaluation of sst1 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7. Regulatory Peptides, 2013, 183, 1-6.	1.9	24
147	Expression and Function of Somatostatin Receptors in Peripheral Nerve Sheath Tumors. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1080-1088.	1.7	23
148	High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event. Journal of Cancer Research and Clinical Oncology, 2012, 138, 397-403.	2.5	23
149	Protein kinase C-mediated mu-opioid receptor phosphorylation and desensitization in rats, and its prevention during early diabetes. Pain, 2016, 157, 910-921.	4.2	23
150	Determination of sites of U50,488H-promoted phosphorylation of the mouse κ opioid receptor (KOPR): disconnect between KOPR phosphorylation and internalization. Biochemical Journal, 2016, 473, 497-508.	3.7	23
151	Neuropeptide S precursor knockout mice display memory and arousal deficits. European Journal of Neuroscience, 2017, 46, 1689-1700.	2.6	23
152	Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. Gynecologic Oncology, 2003, 89, 385-390.	1.4	22
153	Expression of the proliferation marker <scp>K</scp> iâ€67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas. Clinical Endocrinology, 2012, 77, 139-145.	2.4	22
154	Immunocytochemical localisation of plasma membrane GHRH receptors in human tumours using a novel anti-peptide antibody. European Journal of Cancer, 2006, 42, 2390-2396.	2.8	19
155	The role of vascular CXCR4 expression in colorectal carcinoma. Histopathology, 2009, 55, 576-586.	2.9	19
156	Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. Regulatory Peptides, 2013, 187, 35-41.	1.9	19
157	<scp>PI3Kγ</scp> integrates c <scp>AMP</scp> and <scp>Akt</scp> signalling of the <scp>μ</scp> â€opioid receptor. British Journal of Pharmacology, 2014, 171, 3328-3337.	5.4	19
158	Identification of Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking. Molecular Endocrinology, 2016, 30, 645-659.	3.7	19
159	Agonist-Dependent and -Independent κ Opioid Receptor Phosphorylation: Distinct Phosphorylation Patterns and Different Cellular Outcomes. Molecular Pharmacology, 2017, 92, 588-600.	2.3	19
160	Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin. Scientific Reports, 2019, 9, 4339.	3.3	19
161	New phosphosite-specific antibodies to unravel the role of GRK phosphorylation in dopamine D2 receptor regulation and signaling. Scientific Reports, 2021, 11, 8288.	3.3	19
162	Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. Journal of Medicinal Chemistry, 2021, 64, 8104-8126.	6.4	18

#	Article	IF	CITATIONS
163	Selective phosphorylation of threonine residues defines CPR84–arrestin interactions of biased ligands. Journal of Biological Chemistry, 2022, 298, 101932.	3.4	18
164	Induction of Proenkephalin Gene Expression in Cultured Bovine Chromaffin Cells Is Dependent on Protein Synthesis of AP-1 Proteins. Journal of Neurochemistry, 2002, 66, 2264-2271.	3.9	17
165	The somatostatin SST2A receptor in the rat trigeminal ganglion. Neuroscience, 2003, 120, 807-813.	2.3	17
166	Interaction of brain somatostatin receptors with the PDZ domains of PSDâ€95. FEBS Letters, 2007, 581, 5173-5177.	2.8	17
167	Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor. Molecular and Cellular Endocrinology, 2014, 387, 44-51.	3.2	17
168	Phosphoproteomic analysis of the mouse brain muâ€opioid (MOP) receptor. FEBS Letters, 2015, 589, 2401-2408.	2.8	17
169	Immunofluorescent identification of neuropeptide B-containing nerve fibers and terminals in the rat hypothalamus. Neuroscience Letters, 2007, 411, 67-71.	2.1	16
170	Agonist-regulated Cleavage of the Extracellular Domain of Parathyroid Hormone Receptor Type 1. Journal of Biological Chemistry, 2010, 285, 8665-8674.	3.4	16
171	Regulation of Spinal Dynorphin 1-17 Release by Endogenous Pituitary Adenylyl Cyclase-Activating Polypeptide in the Male Rat: Relevance of Excitation via Disinhibition. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 328-335.	2.5	16
172	VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235. Endocrine Connections, 2015, 4, 18-26.	1.9	16
173	Delta-opioid receptor-immunoreactive neurons in the rat cranial sensory ganglia. Brain Research, 2005, 1043, 225-230.	2.2	15
174	Diagnosis of chronic disseminated candidosis from liver biopsies by a novel PCR in patients with haematological malignancies. Clinical Microbiology and Infection, 2012, 18, 1010-1016.	6.0	15
175	Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade l–IV astrocytic brain tumors. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1227-1237.	2.5	15
176	Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1921-1932.	2.5	15
177	The semantics of procedures and diseases in SNOMED CT. Methods of Information in Medicine, 2006, 45, 354-8.	1.2	15
178	Real-Time Monitoring of Somatostatin Receptor-cAMP Signaling in Live Pituitary. Endocrinology, 2010, 151, 4560-4565.	2.8	14
179	Analgesic treatment with buprenorphine should be adapted to the mouse strain. Pharmacology Biochemistry and Behavior, 2020, 191, 172877.	2.9	14
180	Somatostatin receptor subtype 1 is a PDZ ligand for synapse-associated protein 97 and a potential regulator of growth cone dynamics. Neuroscience, 2008, 157, 833-843.	2.3	13

#	Article	IF	CITATIONS
181	Illness behaviour of general practitioners—a cross-sectional survey. Occupational Medicine, 2017, 67, 33-37.	1.4	13
182	Tyramide signal amplification in brain immunocytochemistry: adaptation to electron microscopy. Journal of Neuroscience Methods, 1999, 88, 55-61.	2.5	12
183	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Child's Nervous System, 2013, 29, 1253-1262.	1.1	12
184	Fineâ€ŧuning somatostatin receptor signalling by agonistâ€selective phosphorylation and dephosphorylation: IUPHAR Review 5. British Journal of Pharmacology, 2014, 171, 1591-1599.	5.4	12
185	Analysis of Somatostatin Receptor 2A Immunohistochemistry, RT-qPCR, and In Vivo PET/CT Data in Patients With Pancreatic Neuroendocrine Neoplasm. Pancreas, 2015, 44, 648-654.	1.1	12
186	Comprehensive Assessment of GPR68 Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody. International Journal of Molecular Sciences, 2019, 20, 5261.	4.1	12
187	Carboxyl-Terminal Receptor Domains Control the Differential Dephosphorylation of Somatostatin Receptors by Protein Phosphatase 1 Isoforms. PLoS ONE, 2014, 9, e91526.	2.5	12
188	Inhibition of protein farnesyltransferase: a possible mechanism of tumor prevention by dehydroepiandrosterone sulfate. Carcinogenesis, 1994, 15, 2649-2652.	2.8	11
189	A Transplantable Phosphorylation Probe for Direct Assessment of G Protein-Coupled Receptor Activation. PLoS ONE, 2012, 7, e39458.	2.5	11
190	Immunohistochemical Localization of CCK1Cholecystokinin Receptors in Normal and Neoplastic Human Tissues. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6149-6155.	3.6	10
191	Effect of Brn-3a deficiency on primary nociceptors in the trigeminal ganglion. Neuroscience Research, 2005, 51, 445-451.	1.9	10
192	Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2481-2493.	2.5	10
193	Immunocytochemical identification of low-affinity NTS2 neurotensin receptors in parietal cells of human gastric mucosa. Journal of Endocrinology, 2006, 191, 121-128.	2.6	9
194	Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract. Amino Acids, 2007, 32, 395-400.	2.7	9
195	SR-17018 Stimulates Atypical µ-Opioid Receptor Phosphorylation and Dephosphorylation. Molecules, 2021, 26, 4509.	3.8	9
196	HA-MOP knockin mice express the canonical µ-opioid receptor but lack detectable splice variants. Communications Biology, 2021, 4, 1070.	4.4	9
197	Bidirectional mereological reasoning in anatomical knowledge bases. Proceedings, 2001, , 607-11.	0.6	9
198	Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors. Cancers, 2021, 13, 3097.	3.7	8

#	Article	IF	CITATIONS
199	Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors. International Journal of Clinical and Experimental Pathology, 2013, 6, 49-54.	0.5	8
200	Expression of the mu-opioid receptor is induced in dentate gyrus granule cells after focal cerebrocortical ischaemia and stimulation of entorhinal afferents. European Journal of Neuroscience, 2005, 22, 1032-1044.	2.6	7
201	A novel G proteinâ€biased agonist at the μ opioid receptor induces substantial receptor desensitisation through G proteinâ€coupled receptor kinase. British Journal of Pharmacology, 2020, , .	5.4	7
202	Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies. Translational Oncology, 2020, 13, 100801.	3.7	7
203	Rapid assessment of G protein signaling of four opioid receptors using a real-time fluorescence-based membrane potential assay. European Journal of Pharmacology, 2021, 890, 173640.	3.5	7
204	Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation. International Journal of Clinical and Experimental Pathology, 2014, 7, 4971-80.	0.5	7
205	Detection of inhibition of HIV-1 protease activity by an enzyme-linked immunosorbent assay (ELISA). Journal of Immunological Methods, 1993, 161, 151-155.	1.4	6
206	Expression changes of somatostatin receptor subtypes sst2A, sst2B, sst3 and sst4 after a cortical contusion trauma in rats. Brain Research, 2002, 930, 191-199.	2.2	6
207	Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist. Life, 2021, 11, 1075.	2.4	6
208	Assessment of G Protein-Coupled Oestrogen Receptor Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody. International Journal of Molecular Sciences, 2022, 23, 5191.	4.1	6
209	Somatostatin Receptors Type 2 and 5 Expression and Localization During Human Pituitary Development. Endocrinology, 2014, 155, 33-39.	2.8	5
210	Does chloride channel accessory 3 have a role in arthritis pain? A study on murine antigen-induced arthritis. Neuroscience Letters, 2014, 576, 40-44.	2.1	5
211	The effects of kratom on restraint–stress-induced analgesia and its mechanisms of action. Journal of Ethnopharmacology, 2017, 205, 178-185.	4.1	5
212	Conversion problems concerning automated mapping from ICD-10 to ICD-9. Methods of Information in Medicine, 1998, 37, 254-9.	1.2	5
213	Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics. Scientific Reports, 2022, 12, 7154.	3.3	5
214	Reassessment of endothelin receptor A expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-8. Peptides, 2015, 66, 19-25.	2.4	4
215	The NPXXY Motif Regulates Î ² -Arrestin Recruitment by the CB1 Cannabinoid Receptor. Cannabis and Cannabinoid Research, 2023, 8, 731-748.	2.9	4
216	Differential regulation of somatostatin receptor dephosphorylation by β-arrestin1 and β-arrestin2. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 263-269.	3.0	3

#	Article	IF	CITATIONS
217	Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells. Endocrine, 2017, 57, 179-182.	2.3	3
218	Reassessment of SST4 Somatostatin Receptor Expression Using SST4-eGFP Knockin Mice and the Novel Rabbit Monoclonal Anti-Human SST4 Antibody 7H49L61. International Journal of Molecular Sciences, 2021, 22, 12981.	4.1	3
219	Knowledge engineering the UMLS. Studies in Health Technology and Informatics, 2000, 77, 701-5.	0.3	3
220	Subword-based text retrieval. , 2003, , .		2
221	The microcephaly gene Donson is essential for progenitors of cortical glutamatergic and GABAergic neurons. PLoS Genetics, 2021, 17, e1009441.	3.5	2
222	Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus. Neuroscience, 2022, 496, 83-95.	2.3	2
223	Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies. BMC Cancer, 2022, 22, .	2.6	2
224	Differential In vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G-protein and Beta-arrestin Signaling at the Human Nociceptin Opioid Receptor. Molecular Pharmacology, 2021, 100, MOLPHARM-AR-2020-000076.	2.3	1
225	Computer-based training and electronic publishing in the health sector: tools and trends. Methods of Information in Medicine, 1997, 36, 149-53.	1.2	1
226	Inhibition of protein farnesyltransferase: a possible mechanism of tumor prevention by dehydroepiandros terone sulfate. Carcinogenesis, 1995, 16, 149-149.	2.8	0
227	Somatostatin. , 2021, , 1-11.		0
228	Somatostatin., 2021,, 1456-1466.		0
229	Opioid Systems. , 2021, , 1193-1197.		Ο
230	Integrated care: an Information Model for Patient Safety and Vigilance Reporting Systems. Studies in Health Technology and Informatics, 2015, 210, 434-8.	0.3	0